ABBV vs DDOG: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Datadog, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-09.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C High Quality
VS
Datadog, Inc. · Technology
$261.09
+45.0% upside to fair value
Grade B High Quality
QuantHub Verdict
DDOG has more upside to fair value (+45.0%). ABBV trades at a lower forward P/E (128.0x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV DDOG
Current Price $261.07 $261.09
Fair Value Estimate $264.30 $378.58
Upside to Fair Value +1.2% +45.0%
Market Cap $461.3B $92.9B
Forward P/E 128.0x 678.5x
EV / EBITDA 31.0x 410.4x
Price / Sales 7.3x 25.3x
Price / FCF 22.1x 86.1x
Revenue Growth YoY +12.4% +32.2%
Gross Margin 70.7% 79.9%
Operating Margin 27.6% -0.7%
Return on Equity 68.0% 3.8%
Dividend Yield 0% 0%
FCF Yield 4.52% 1.16%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ABBV — AbbVie Inc.
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
DDOG — Datadog, Inc.
Datadog, Inc. is a leading provider of cloud-scale monitoring and analytics software for developers, IT operations teams, and business users in the technology sector. The company exhibits strong business quality with a durable competitive moat supported by high gross margins of 79.9% and rapid revenue growth of 32.2% in the most recent quarter. Despite this, the stock trades at a very high valuat…
Accumulation Zones
Metric ABBV DDOG
Zone Low $198.23 $283.94
Zone High $224.66 $321.79
In Buy Zone? No Yes
← ABBV Research    DDOG Research →    All Research